David Crean

California Life Sciences Association (CLSA) is the largest and most influential life sciences advocacy and business leadership organization in California. The non-profit company is based in South San Francisco, CA, and has offices in other locations as well. The company works closely with industry, government, academia, and others to shape public policy, improve access to innovative technologies, and grow California's life sciences economy. CLSA serves biotechnology, pharmaceutical, medical device, and diagnostics companies, research universities and institutes, investors, and service providers throughout the state. Mike Guerra has been the CEO of the company since 2019.

Mesa Verde Venture Partners LP seeks investment opportunities in companies located in the US. The fund targets companies operating in the fields of drug discovery/tools, medical devices & diagnostics and healthcare information technology. It provides financing for early stage capital requirements with an investment size of $0.5 - $1.5 million per company.

The Securities Investor Protection Corporation either acts as trustee or works with an independent court-appointed trustee in a missing asset case to recover funds. The statute that created SIPC provides that customers of a failed brokerage firm receive all non-negotiable securities that are already registered in their names or in the process of being registered. Recovered funds are used to replenish SIPC's reserve in the event that the reserve is tapped in the early stages of a liquidation proceeding.

Financial Industry Regulatory Authority, Inc. engages in the provision of securities regulation, complementary compliance, and technology-based services. Its services include writing and enforcing rules governing the activities of securities firms with brokers, examining firms for compliance with those rules, fostering market transparency, and educating investors. The company was founded in 2007 and is headquartered in Washington, DC.

Paracrine, Inc. is a biotechnology company that is developing a device-based autologous multifactorial cell therapy platform to treat chronic conditions. The private company is based in San Diego, CA. The company's cell therapy platform has multiple mechanisms of action that can address the underlying pathology of several debilitating chronic diseases. Paracrine is currently advancing multiple late-stage ide clinical trials based on robust prior data. The CEO of the company is Christopher James Calhoun.

BIOCOM provides scientific and technological services. The firm focuses that positively influence the growth of the life science industry, including capital formation, public policy, workforce development and scientific discovery and development. The company was founded in 1995 and is headquartered in San Diego, CA.